Press Releases

Date Title and Summary Additional Formats
Toggle Summary Amicus Therapeutics to Present at Bank of America Merrill Lynch 2018 Health Care Conference
CRANBURY, N.J. , May 09, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that John F. Crowley , Chairman and Chief Executive Officer, will participate in a fireside chat at the Bank of America Merrill Lynch 2018 Health Care Conference in Las Vegas, NV on Tuesday, May 15,
View HTML
Toggle Summary Amicus Therapeutics Announces First Quarter 2018 Financial Results and Corporate Updates
Continued Global Galafold ® (Migalastat) Adoption and Expansion – Reaffirms FY18 Revenue Guidance of $75M-$85M at Top End of Range Significant Momentum with Pompe Clinical, Regulatory and Manufacturing Activities - GMP Manufacturing Campaigns of ATB200 Drug Substance and Drug Product Completed at
View HTML
Toggle Summary Amicus Therapeutics to Announce First Quarter 2018 Financial Results on May 8, 2018
CRANBURY, N.J. , April 26, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on Tuesday, May 8, 2018 at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2018 . The call will be hosted by John F.
View HTML
Toggle Summary Amicus Therapeutics Honors Fabry Disease Awareness Month and International Pompe Day
CRANBURY, N.J. , April 17, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) is participating in several activities in April to honor Fabry Disease Awareness Month and International Pompe Day. The Fabry community has designated the month of April to honor and recognize those who living
View HTML
Toggle Summary Amicus Therapeutics Announces Approval of Galafold® (Migalastat) for Fabry Disease in Japan
First Amicus Medicine and First Oral Precision Medicine for Fabry Patients with an Amenable Mutation in Japan CRANBURY, N.J. , March 22, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved the oral small
View HTML
Toggle Summary Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2018
CRANBURY, N.J. , March 05, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced upcoming presentations at two investor conferences in March. John F. Crowley , Chairman and Chief Executive Officer, will present a corporate overview and fireside chat at the Cowen & Company 38th
View HTML
Toggle Summary Amicus Therapeutics Announces Full-Year 2017 Financial Results and 2018 Corporate Updates
Galafold Expansion Continues with 360+ Fabry Patients Treated Today - on Track to Achieve FY18 Revenue Guidance of $75M-$85M Significant Progress Across Pompe Clinical, Regulatory and Manufacturing Activities - Successfully Completed First GMP Manufacturing Campaign of ATB200 Drug Substance at
View HTML
Toggle Summary Amicus Therapeutics Launches Healing Beyond Disease™ Initiatives to Change People’s Lives Living with Rare Diseases
Unique Volunteerism, Mentorship, Giving, Global Access and Advocacy Programs Under Long-term Healing Beyond Disease Initiatives CRANBURY, N.J. , Feb. 27, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) is honoring Rare Disease Day this week with the launch of Healing Beyond Disease™, a
View HTML
Toggle Summary Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock
CRANBURY, N.J. , Feb. 21, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced the closing of its previously announced offering of common stock. The Company issued a total of 19,354,839 shares in the offering at a price of $15.50 per share.
View HTML
Toggle Summary Amicus Therapeutics to Announce Full-Year 2017 Financial Results on February 28, 2018
CRANBURY, N.J. , Feb. 21, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on Wednesday, February 28, 2018 at 8:30 a.m. ET to discuss financial results for the full year ended December 31, 2017 . The call will be hosted by John F.
View HTML